Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy

Haodi Wu, Jaecheol Lee, Ludovic G. Vincent, Qingtong Wang, Mingxia Gu, Feng Lan, Jared M. Churko, Karim I. Sallam, Elena Matsa, Arun Sharma, Joseph D. Gold, Adam J. Engler, Yang Kevin Xiang, Donald M Bers, Joseph C. Wu

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

β-Adrenergic signalingpathwaysmediate key aspects of cardiac function. Its dysregulation is associated with a range of cardiac diseases, including dilated cardiomyopathy (DCM). Previously, we established an iPSC model of familial DCM from patients with a mutation in TNNT2, a sarcomeric protein. Here, we found that the β-adrenergic agonist isoproterenol induced mature β-adrenergic signaling in iPSCderived cardiomyocytes (iPSC-CMs) but that this pathway was blunted in DCM iPSC-CMs. Although expression levels of several β-adrenergic signaling components were unaltered between control and DCM iPSC-CMs, we found that phosphodiesterases (PDEs) 2A and PDE3A were upregulated in DCM iPSC-CMs and that PDE2A was also upregulated in DCM patient tissue. We further discovered increased nuclear localization of mutant TNNT2 and epigenetic modifications of PDE genes in both DCM iPSC-CMs and patient tissue. Notably, pharmacologic inhibition of PDE2A and PDE3A restored cAMP levels and ameliorated the impaired β-adrenergic signaling of DCM iPSC-CMs, suggesting therapeutic potential.

Original languageEnglish (US)
Pages (from-to)89-100
Number of pages12
JournalCell Stem Cell
Volume17
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Type 2 Cyclic Nucleotide Phosphodiesterases
Type 3 Cyclic Nucleotide Phosphodiesterases
Dilated Cardiomyopathy
Epigenomics
Adrenergic Agents
Cardiac Myocytes
Adrenergic Agonists
Phosphoric Diester Hydrolases
Isoproterenol
Heart Diseases

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine
  • Genetics

Cite this

Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy. / Wu, Haodi; Lee, Jaecheol; Vincent, Ludovic G.; Wang, Qingtong; Gu, Mingxia; Lan, Feng; Churko, Jared M.; Sallam, Karim I.; Matsa, Elena; Sharma, Arun; Gold, Joseph D.; Engler, Adam J.; Xiang, Yang Kevin; Bers, Donald M; Wu, Joseph C.

In: Cell Stem Cell, Vol. 17, No. 1, 2015, p. 89-100.

Research output: Contribution to journalArticle

Wu, H, Lee, J, Vincent, LG, Wang, Q, Gu, M, Lan, F, Churko, JM, Sallam, KI, Matsa, E, Sharma, A, Gold, JD, Engler, AJ, Xiang, YK, Bers, DM & Wu, JC 2015, 'Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy', Cell Stem Cell, vol. 17, no. 1, pp. 89-100. https://doi.org/10.1016/j.stem.2015.04.020
Wu, Haodi ; Lee, Jaecheol ; Vincent, Ludovic G. ; Wang, Qingtong ; Gu, Mingxia ; Lan, Feng ; Churko, Jared M. ; Sallam, Karim I. ; Matsa, Elena ; Sharma, Arun ; Gold, Joseph D. ; Engler, Adam J. ; Xiang, Yang Kevin ; Bers, Donald M ; Wu, Joseph C. / Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy. In: Cell Stem Cell. 2015 ; Vol. 17, No. 1. pp. 89-100.
@article{ab9043332eb74573a9e272dcf3a3ef91,
title = "Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy",
abstract = "β-Adrenergic signalingpathwaysmediate key aspects of cardiac function. Its dysregulation is associated with a range of cardiac diseases, including dilated cardiomyopathy (DCM). Previously, we established an iPSC model of familial DCM from patients with a mutation in TNNT2, a sarcomeric protein. Here, we found that the β-adrenergic agonist isoproterenol induced mature β-adrenergic signaling in iPSCderived cardiomyocytes (iPSC-CMs) but that this pathway was blunted in DCM iPSC-CMs. Although expression levels of several β-adrenergic signaling components were unaltered between control and DCM iPSC-CMs, we found that phosphodiesterases (PDEs) 2A and PDE3A were upregulated in DCM iPSC-CMs and that PDE2A was also upregulated in DCM patient tissue. We further discovered increased nuclear localization of mutant TNNT2 and epigenetic modifications of PDE genes in both DCM iPSC-CMs and patient tissue. Notably, pharmacologic inhibition of PDE2A and PDE3A restored cAMP levels and ameliorated the impaired β-adrenergic signaling of DCM iPSC-CMs, suggesting therapeutic potential.",
author = "Haodi Wu and Jaecheol Lee and Vincent, {Ludovic G.} and Qingtong Wang and Mingxia Gu and Feng Lan and Churko, {Jared M.} and Sallam, {Karim I.} and Elena Matsa and Arun Sharma and Gold, {Joseph D.} and Engler, {Adam J.} and Xiang, {Yang Kevin} and Bers, {Donald M} and Wu, {Joseph C.}",
year = "2015",
doi = "10.1016/j.stem.2015.04.020",
language = "English (US)",
volume = "17",
pages = "89--100",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy

AU - Wu, Haodi

AU - Lee, Jaecheol

AU - Vincent, Ludovic G.

AU - Wang, Qingtong

AU - Gu, Mingxia

AU - Lan, Feng

AU - Churko, Jared M.

AU - Sallam, Karim I.

AU - Matsa, Elena

AU - Sharma, Arun

AU - Gold, Joseph D.

AU - Engler, Adam J.

AU - Xiang, Yang Kevin

AU - Bers, Donald M

AU - Wu, Joseph C.

PY - 2015

Y1 - 2015

N2 - β-Adrenergic signalingpathwaysmediate key aspects of cardiac function. Its dysregulation is associated with a range of cardiac diseases, including dilated cardiomyopathy (DCM). Previously, we established an iPSC model of familial DCM from patients with a mutation in TNNT2, a sarcomeric protein. Here, we found that the β-adrenergic agonist isoproterenol induced mature β-adrenergic signaling in iPSCderived cardiomyocytes (iPSC-CMs) but that this pathway was blunted in DCM iPSC-CMs. Although expression levels of several β-adrenergic signaling components were unaltered between control and DCM iPSC-CMs, we found that phosphodiesterases (PDEs) 2A and PDE3A were upregulated in DCM iPSC-CMs and that PDE2A was also upregulated in DCM patient tissue. We further discovered increased nuclear localization of mutant TNNT2 and epigenetic modifications of PDE genes in both DCM iPSC-CMs and patient tissue. Notably, pharmacologic inhibition of PDE2A and PDE3A restored cAMP levels and ameliorated the impaired β-adrenergic signaling of DCM iPSC-CMs, suggesting therapeutic potential.

AB - β-Adrenergic signalingpathwaysmediate key aspects of cardiac function. Its dysregulation is associated with a range of cardiac diseases, including dilated cardiomyopathy (DCM). Previously, we established an iPSC model of familial DCM from patients with a mutation in TNNT2, a sarcomeric protein. Here, we found that the β-adrenergic agonist isoproterenol induced mature β-adrenergic signaling in iPSCderived cardiomyocytes (iPSC-CMs) but that this pathway was blunted in DCM iPSC-CMs. Although expression levels of several β-adrenergic signaling components were unaltered between control and DCM iPSC-CMs, we found that phosphodiesterases (PDEs) 2A and PDE3A were upregulated in DCM iPSC-CMs and that PDE2A was also upregulated in DCM patient tissue. We further discovered increased nuclear localization of mutant TNNT2 and epigenetic modifications of PDE genes in both DCM iPSC-CMs and patient tissue. Notably, pharmacologic inhibition of PDE2A and PDE3A restored cAMP levels and ameliorated the impaired β-adrenergic signaling of DCM iPSC-CMs, suggesting therapeutic potential.

UR - http://www.scopus.com/inward/record.url?scp=84937022594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937022594&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2015.04.020

DO - 10.1016/j.stem.2015.04.020

M3 - Article

VL - 17

SP - 89

EP - 100

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 1

ER -